ACS Chemical Neuroscience · 2017 · 46 citations · 59 references
Life SciencesNeuroscienceToxicologyNeurochemistryNeurodegenerationNeuropharmacologyAlzheimer DiseaseCholinergic NeurochemistryNeurodegeneration MechanismsNeurodegenerative DiseasesNeurodegenerative DisordersNeuroprotectionAche InhibitionAmyloid Beta AggregationAmyloid Beta PeptidesAmyloid-associated NeurotoxicityAmyloid-beta-induced NeurotoxicityChelate EffectNeuroprotective AgentsOligomerization
The biphenyl neolignan honokiol is a neuroprotectant which has been proposed as a treatment for central nervous system disorders such as Alzheimer’s disease (AD). The death of cholinergic neurons in AD is attributed to multiple factors, including accumulation and fibrillation of amyloid beta peptide (Aβ) within the brain; metal ion toxicity; and oxidative stress. In this study, we used a transgenic Caenorhabditis elegans model expressing full length Aβ 42 as a convenient in vivo system for examining the effect of honokiol against Aβ-induced toxicity. Furthermore, honokiol was evaluated for its ability to inhibit Aβ 42 oligomerization and fibrillation; inhibit acetylcholinesterase and butyrylcholinesterase; scavenge 2,2-diphenyl-1-picrylhydrazyl (DPPH) radicals; and chelate iron(II). Honokiol displayed activity similar to that of resveratrol and (−)-epigallocatechin gallate (EGCG) in delaying Aβ 42 -induced paralysis in C. elegans, and it exhibited moderate-to-weak ability to inhibit Aβ 42 on-pathway aggregation, inhibit cholinesterases, scavenge DPPH radicals, and chelate iron(II). Moreover, honokiol was found to be chemically stable relative to EGCG, which was highly unstable. Together with its good drug-likeness and brain availability, these results suggest that honokiol may be amenable to drug development and that the synthesis of honokiol analogues to optimize these properties should be considered.
59
Common Structure of Soluble Amyloid Oligomers Implies Common Mechanism of Pathogenesis
Rakez Kayed, Elizabeth Head, Jennifer L. Thompson et al. · Science · 2003 · 4.1K citations
HIGH ABSORPTION BUT VERY LOW BIOAVAILABILITY OF ORAL RESVERATROL IN HUMANS
Thomas Walle, Faye Hsieh, Mark H. DeLegge et al. · Drug Metabolism and Disposition · 2004 · 1.8K citations
Self-Propagating, Molecular-Level Polymorphism in Alzheimer's ß-Amyloid Fibrils
Aneta T. Petkova, Richard D. Leapman, Zhihong Guo et al. · Science · 2005 · 1.7K citations